Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Preliminary report of a phase 2 study of gemtuzumab ozogamicin in combination with cytarabine and daunorubicin in patients <60 years of age with de novo acute myeloid leukemia

Preliminary report of a phase 2 study of gemtuzumab ozogamicin in combination with cytarabine and daunorubicin in patients <60 years of age with de novo acute myeloid leukemia. ASCO. 2003; (#2325).


Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.